June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Efficacy and safety of ranibizumab treatment guided by functional and/or anatomical criteria in patients with neovascular age-related macular degeneration: results from the OCTAVE study
Author Affiliations & Notes
  • Petr Kolar
    University Eye Clinic of Masaryk University and Univesity Hospital Brno, Brno, Czech Republic
  • Giovanni Staurenghi
    Az.Osp.Luigi Sacco-Polo,Universitario Università degli Studi , Milan, Italy
  • Cornelia Dunger-Baldauf
    Novartis Pharma AG, Basel, Switzerland
  • Wayne Macfadden
    Novartis Pharma AG, Basel, Switzerland
  • Footnotes
    Commercial Relationships   Petr Kolar, Bayer (F), Novartis, Bayer (C); Giovanni Staurenghi, Novartis (C); Cornelia Dunger-Baldauf, Novartis (E); Wayne Macfadden, Novartis (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 903. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Petr Kolar, Giovanni Staurenghi, Cornelia Dunger-Baldauf, Wayne Macfadden; Efficacy and safety of ranibizumab treatment guided by functional and/or anatomical criteria in patients with neovascular age-related macular degeneration: results from the OCTAVE study. Invest. Ophthalmol. Vis. Sci. 2017;58(8):903.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Ranibizumab is approved for the treatment of neovascular AMD (nAMD) worldwide. Retreatment decisions in patients with nAMD are often guided by vision loss; however, evidence suggests that anatomical changes may precede visual loss. Anatomical monitoring using optical coherence tomography (OCT) in addition to visual assessments may help physicians with their retreatment decisions in patients treated with ranibizumab. Here we present the efficacy and safety of two treatment regimens of ranibizumab 0.5 mg, based on functional and/or anatomical retreatment criteria, in patients with nAMD.

Methods : OCTAVE was a 24-month, Phase IIIb, randomized, multicenter, double-masked study conducted in 24 countries. Patients were initially randomized 1:1 into one of two groups, in which re-treatment was based on criteria guided by (i) loss of BCVA due to nAMD (Gp I; n=335) or (ii) BCVA loss due to nAMD and/or signs of disease activity on OCT(Gp II; n=336). The study was terminated prematurely, as the use of OCT became the standard of care in re-treatment decisions after the project was initiated. Presented here are efficacy data from patients who completed at least 12 months, and safety data from the entire population. The data were analyzed using descriptive statistics.

Results : Overall, 671 patients were enrolled in this study. The baseline demographics and ocular characteristics were well balanced in both groups (Table 1). The mean change in BCVA (±SD) from baseline in patients completing 12months of follow-up in Gp I and Gp II was 6.7 (±13.48; n =151) and 8.3 (±13.53; n=154) ETDRS letters, respectively [p=0.3, 95% CI (-1.44; 4.64)] (Figure 1). The proportion of patients gaining ≥5, ≥10, and ≥15 letters at Month 12 is shown in Figure 1. The most commonly reported ocular AEs in both groups (Gp I/II; n=334/336) were increase in intra-ocular pressure (3.6%/ 6.3%), conjunctival hemorrhage (5.7%/3%), and eye pain (3.0%/2.7%). Most common non-ocular AEs (Gp I/II; n=334/336) were nasopharyngitis (7.2%/3.3%), hypertension (5.4%/4.8%), and influenza (4.5%/4.5%).

Conclusions : OCTAVE showed that ranibizumab treatment led to significant visual gains regardless of the retreatment criteria. This study further supports the well-established safety and efficacy profile of ranibizumab in patients with nAMD.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×